LBO — BELLEVUE MEDICAL CENTER
IRR: 16.8% | MOIC: 2.17x
🛡️ Public data only — no PHI permitted on this instance.
← DashboardPRFProfileMEMIC MemoBRGBridgeCIComp IntelSCNScenariosAIMLDCFDCFLBOLBOFIN3-StmtMKTMarketDENDenialRETReturnsLVRLeversWFLWaterfallPLYPlaybookTRDTrendsPREDPredictedMEM2Memo
16.8%
IRR
2.17x
MOIC
$129.7M
Entry EV
$196.8M
Exit EV
$66.7M
Equity Invested
Sources & Uses
S&UTotal · $129.7M| Item | Amount | % | Distribution |
|---|---|---|---|
| Senior Debt | $50.4M | 38.8% | |
| Sub Debt | $12.6M | 9.7% | |
| Equity | $66.7M | 51.5% | |
| Enterprise Value | $125.9M | 97.1% | |
| Transaction Fees | $3.8M | 2.9% | |
| Total Uses | $129.7M | 100.0% |
Interpretation
INTAt 2.17x MOIC and 16.8% IRR over 5 years, this deal meets the 15-20% range — acceptable with operational upside.
Key drivers: Check the EBITDA bridge to identify highest-probability levers, the debt schedule for leverage trajectory, or the challenge solver to see what breaks the deal.
Returns Waterfall
WFL| Component | Value |
|---|---|
| Exit Ebitda | $18.7M |
| Exit Ev | $196.8M |
| Net Debt At Exit | $51.8M |
| Equity At Exit | $145.0M |
| Equity Invested | $66.7M |
| Total Value Created | $78.3M |
| Value From Growth | $64.7M |
| Value From Multiple | $6.3M |
| Value From Deleveraging | $11.1M |